Hongbo Lu Acquires 58,823 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Key Points

• Hongbo Lu, Director of Zenas BioPharma, acquired 58,823 shares of the company at an average price of $17.00 per share, totaling approximately $999,991.
• Zenas BioPharma's shares recently traded at $27.76, with a market capitalization of $1.17 billion and a P/E ratio of -7.82.
• Multiple analysts have given mixed ratings on Zenas BioPharma, with a consensus rating of "Moderate Buy" and a target price of approximately $38.33.

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) Director Hongbo Lu acquired 58,823 shares of the company's stock in a transaction on Friday, September 13th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $999,991.00. Following the completion of the purchase, the director directly owned 58,823 shares of the company's stock, valued at approximately $999,991. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Hongbo Lu also recently made the following trade(s):

• On Tuesday, October 7th, Hongbo Lu acquired 263,160 shares of Zenas BioPharma stock. The stock was acquired at an average cost of $19.00 per share, for a total transaction of $5,000,040.00.

Zenas BioPharma Stock Performance

Shares of Zenas BioPharma stock traded up $1.86 during trading hours on Thursday, reaching $27.76. The company's stock had a trading volume of 830,731 shares, compared to its average volume of 203,089. Zenas BioPharma, Inc. has a one year low of $5.83 and a one year high of $28.72. The company has a market capitalization of $1.17 billion and a P/E ratio of -7.82. The stock's fifty day simple moving average is $18.40 and its two-hundred day simple moving average is $13.11.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Institutional Investors Weigh In On Zenas BioPharma

Hedge funds have recently bought and sold shares of the stock. Nuveen LLC bought a new stake in Zenas BioPharma during the first quarter valued at approximately $250,000. New York State Common Retirement Fund bought a new stake in Zenas BioPharma during the first quarter valued at approximately $49,000. Jefferies Financial Group Inc. bought a new stake in Zenas BioPharma during the first quarter valued at approximately $348,000. Geode Capital Management LLC lifted its position in Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Zenas BioPharma by 71.3% during the second quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock valued at $191,000 after purchasing an additional 8,207 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zenas BioPharma in a report on Wednesday. Wall Street Zen downgraded shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a report on Friday, September 26th. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Zenas BioPharma in a research report on Thursday. Finally, Wedbush boosted their price target on shares of Zenas BioPharma from $35.00 to $40.00 and gave the company an "outperform" rating in a research report on Thursday. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zenas BioPharma presently has an average rating of "Moderate Buy" and a consensus target price of $38.33.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.